Christopher Henney
Chairman chez CYCLACEL PHARMACEUTICALS, INC.
Profil
Christopher S.
Henney was the founder of ICOS Corp.
(founded in 1989) and Dendreon Corp.
(founded in 1992), where he held the title of Director, Executive VP & Scientific Director and Chairman respectively.
Dr. Henney is also the founder of Immunex Corp...
Dr. Henney's current job is Chairman at Cyclacel Pharmaceuticals, Inc. since 2006.
Dr. Henney's former jobs include Chairman, President & Chief Executive Officer at Cascadian Therapeutics LLC (2005-2018), Chairman at Biomira, Inc. (2005-2007), Vice Chairman at Xcyte Therapies, Inc., Chairman at Anthera Pharmaceuticals, Inc. (2005-2016), Chairman at SGX Pharmaceuticals, Inc., Chairman at Allostera Pharma, Inc. (2010-2013), Director at Bio-Techne Corp., Director at Sarepta Therapeutics, Inc. (2009-2010), Director at Mymetics Corp.
(2011), Independent Director at Prothena Corp.
Plc (2013-2022).
Dr. Henney's education includes undergraduate and doctorate degrees from the University of Birmingham.
Postes actifs de Christopher Henney
| Sociétés | Poste | Début |
|---|---|---|
| CYCLACEL PHARMACEUTICALS, INC. | Chairman | 26/08/2020 |
Anciens postes connus de Christopher Henney
| Sociétés | Poste | Fin |
|---|---|---|
| PROTHENA CORPORATION PLC | Director/Board Member | 17/05/2022 |
| CASCADIAN THERAPEUTICS INC (USA) | Chief Executive Officer | 04/04/2016 |
| ANTHERA PHARMACEUTICALS, INC. | Chairman | 01/01/2016 |
Allostera Pharma, Inc.
 Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Chairman | 09/09/2013 |
| MYMETICS CORPORATION | Director/Board Member | 01/11/2011 |
Formation de Christopher Henney
| University of Birmingham | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| BIO-TECHNE CORPORATION | Health Technology |
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| MYMETICS CORPORATION | Health Technology |
| ANTHERA PHARMACEUTICALS, INC. | Health Technology |
| CYCLACEL PHARMACEUTICALS, INC. | Health Technology |
| PROTHENA CORPORATION PLC | Health Technology |
| Entreprise privées | 9 |
|---|---|
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Health Technology |
ICOS Corp.
 ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | Health Technology |
Biomira, Inc.
 Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | Health Services |
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
| Xcyte Therapies, Inc. | Health Technology |
Cascadian Therapeutics LLC
 Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA. | Health Technology |
SGX Pharmaceuticals, Inc.
 SGX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA. | Health Technology |
Fred Hutchinson Cancer Research Center
 Fred Hutchinson Cancer Research Center Miscellaneous Commercial ServicesCommercial Services Fred Hutchinson Cancer Research Center is a non-profit organization which provides research and testing services. The company was founded in 1965 and is headquartered in Seattle, WA. | Commercial Services |
Allostera Pharma, Inc.
Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Distribution Services |
